Tuesday, September 2, 2008

Medical News Today News Alert

Dear Subscriber,

Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.

To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .


----------------------------------------------
** BREAST CANCER News **

No news for this category today.

----------------------------------------------
** CANCER / ONCOLOGY News **

World Cancer Declaration Sets Ambitious Targets For 2020
http://www.medicalnewstoday.com/articles/119931.php
A summit of more than 60 high-level policymakers, leaders and health experts have adopted a global plan aimed at tackling the growing cancer crisis in developing countries.The plan, contained in the World Cancer Declaration, recommends a set of 11 cancer-busting targets for 2020 and outlines priority steps that need to be taken in order to meet them.

Landmark Study Opens Door To New Cancer, Aging Treatments
http://www.medicalnewstoday.com/articles/119902.php
Researchers at The Wistar Institute have deciphered the structure of the active region of telomerase, an enzyme that plays a major role in the development of nearly all human cancers. The landmark achievement opens the door to the creation of new, broadly effective cancer drugs, as well as anti-aging therapies.

New Approach To Treating Endometrial Cancer Discovered By TGen And Washington University Researchers
http://www.medicalnewstoday.com/articles/119882.php
Researchers at the Translational Genomics Research Institute (TGen) has announced a new approach to treating endometrial cancer patients that not only stops the growth of tumors, but kills the cancer cells.

----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **

CMAJ Study Reveals Higher Anaphylaxis Rates After HPV Vaccination
http://www.medicalnewstoday.com/articles/119955.php
The estimated rate of anaphylaxis in young women after human papillomavirus (HPV) vaccination was significantly higher - 5 to 20 fold - than that identified in comparable school-based vaccination programs, according to a study published in <i>CMAJ</i> <a href="http://www.

----------------------------------------------
** COLORECTAL CANCER News **

No news for this category today.

----------------------------------------------
** LUNG CANCER News **

No news for this category today.

----------------------------------------------
** LYMPHOMA / LEUKEMIA News **

REVLIMID(R) Demonstrates Activity Against Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
http://www.medicalnewstoday.com/articles/119906.php
Celgene International Sàrl (Nasdaq:CELG) announced the publication of peer-reviewed data from a Phase II study of REVLIMID in relapsed or refractory aggressive non-Hodgkin's lymphoma in the <i>Journal of Clinical Oncology.

----------------------------------------------
** PROSTATE / PROSTATE CANCER News **

MR-Guided Biopsy Of The Prostate: An Overview Of Techniques And A Systematic Review
http://www.medicalnewstoday.com/articles/119949.php
UroToday.com - Next to digital rectal examination and PSA level, biopsy of the prostate is an essential procedure for determining optimal treatment. Systematic TRUSBx is the gold standard, but it fails to detect numerous tumors.

How Much Tissue Sampling Is Required When Unsuspected Minimal Prostate Carcinoma Is Identified On Transurethral Resection?
http://www.medicalnewstoday.com/articles/119900.php
UroToday.com - Transurethral resection of prostate (TURP) is still a common urological procedure that is primarily used in the current practice for the surgical management of benign prostatic hyperplasia.

Finnish Multicenter Study Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer
http://www.medicalnewstoday.com/articles/119898.php
UroToday.com - The FinnProstate Study VII (FPVII) is conducted as an open-label, randomized, controlled, parallel-group, multicenter clinical trial comparing intermittent and continuous ADT in patients with advanced PC.

-------------------------------------------------------------

You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .

No comments: